Modeling the progression of Type 2 diabetes with underlying obesity
Fig 4
Dynamics of glucose, insulin and functional beta-cell mass level for patient A with mild obesity (X approaches 0.17 progressively).
This figure describes the impact of the controlled obesity-related factor on the alleviation of diabetes. In contrast to the occurrence of beta-cell failure and subsequent insulin deficiency in Fig 2, hyperinsulinemia would occur to patient A on day 15460 and stay in the remainder of the life of this patient with undamaged pancreatic function. The glucose levels can be controlled below 125 mg/dl before day 20053, indicating a deferral of 38 years to develop diabetes compared with the condition in Fig 2. In addition, a moderate glycemic level, less than 130 mg/dl, can be maintained in the later life of this patient.